TD Cowen raised the firm’s price target on Gilead (GILD) to $95 from $85 and keeps a Buy rating on the shares. The firm updated its model ...

Truist analyst Asthika Goonewardene raised the firm’s price target on Gilead (GILD) to $97 from $83 and keeps a Hold rating on the ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

"The biopharmaceutical industry is poised for a recovery, fueled by multiple FDA approvals leading to a rebound in companies that have seen declines in market capitalization in previous quarters, such ...

Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2024 Earnings Call Transcript November 6, 2024 Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $2.02, expectations were $1.53. Operator: Good ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

An ex-Gilead worker who says he was illegally fired for refusing to steal confidential material isn’t protected by a ...

LB Denzel Perryman, OL Trey Pipkins III, former Chargers outside linebacker Larry English and many volunteers gathered at U.S ...

A Pennsylvania federal district court denied summary judgment to Gilead Sciences, Inc. on the wrongful discharge claim under state law of an employed at-will therapeutic specialist who sold its ...

Born in Lincolnville, South Carolina, Dr. Pernessa Seele has dedicated over 37 years to bridging the gap between faith and ...

Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...